Company news
Amgen Inc. (NASDAQ:AMGN) news
Every Amgen Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
September 18, 2026
FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
September 14, 2026
In the PAPILLON Study, First-Line Amivantamab-Chemotherapy Demonstrates the Longest Overall Survival Reported for EGFR Exon 20 Insertion-Positive Advanced NSCLC
September 14, 2026
Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
September 13, 2026
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
September 9, 2026
IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
September 8, 2026
AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
September 2, 2026
AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
August 31, 2026
TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
August 27, 2026
AMGEN TO OPEN NEW SCIENCE & INNOVATION CENTER IN GENOME VALLEY, HYDERABAD
August 12, 2026
AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
August 4, 2026
AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND
July 30, 2026
Amgen : POSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN'S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKE
July 29, 2026
AMGEN ANNOUNCES WEBCAST OF 2026 SECOND QUARTER FINANCIAL RESULTS
July 28, 2026
Amgen : Statement on FDA Data Submission for TAVNEOS® (avacopan)
July 24, 2026
Amgen Ecovation®: How Amgen Builds Sustainability Into Biotech
July 8, 2026
Amgen : What a Landmark Real-World Study Reveals About Thyroid Eye Disease
June 22, 2026
Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
June 7, 2026
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
June 7, 2026
AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
June 4, 2026
AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
June 3, 2026
Amgen : EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
June 1, 2026
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
May 31, 2026
Amgen : Approach to AI-Enabled Clinical Development
May 20, 2026
AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH
May 19, 2026
Middle East and Africa Wearable Injectors Market Trends and Forecast Report 2026-2035 Featuring Amgen, BD, Biocon, Gerresheimer, Insulet, J&J, Medtronic, Roche, West Pharmaceutical, Ypsomed
May 18, 2026
Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top Developers - Amgen, Hoffmann-La Roche, J&J, Xencor, Biocytogen - Unlocking New Precision, Immune Activation, and Therapeutic Potential
May 12, 2026
Procrit (Amgen) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
May 7, 2026
AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR
May 4, 2026
Blincyto (blinatumomab: Amgen) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
May 1, 2026
AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
April 30, 2026
TOMI Environmental Solutions, Inc. Sees Strong Interest In Its Solutions at INTERPHEX 2026
April 27, 2026
AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS
April 24, 2026
AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
April 22, 2026
Liver Failure: Amgen Continues Marketing Avacopan (Tavneos) in the United States
April 7, 2026
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
April 6, 2026
Global Familial Hypercholesterolemia Treatment Market Led by North America as Amgen and Novartis Expand Therapies
April 2, 2026
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
April 1, 2026
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
March 28, 2026
Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
March 12, 2026
AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
March 5, 2026
AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
March 4, 2026
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
March 3, 2026
AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
February 24, 2026
MATTERWORKS, INC. ANNOUNCES UPDATE TO LEADERSHIP TEAM
February 17, 2026
AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
February 13, 2026
BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration
February 5, 2026
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
February 3, 2026
AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
January 28, 2026
Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference
January 21, 2026